Pharmerit's staff contributions to ISPOR Madrid

 

Pharmerit’s staff contributions to ISPOR 14th annual European congress

Podium presentations

 

Session I: Monday, 7 November: 11:30 – 12:30

• New approaches for effective use of data: better synthesis and enhanced power:The power of assumptions (DA3)

 

Session II: Monday, 7 November: 15:15 – 16:15

• Merging PRO and utility assessment: does the gap indeed get smaller? Combining DCE and TTO into a single value function (UT1)

 

Poster presentations

 

Session I: Sunday, 6 November 12:00-20:00

• Infection:Comparing the efficacy and tolerability of anti-retroviral therapy in treatment-naïve HIV-1 infected adults: a systematic review of randomized clinical trials and Bayesian mixed treatment comparisons including atazanavir/r, darunavir/r, lopinavir/r, and efavirenz (PIN3)
• Infection:Clinical and economic burden of invasive fungal infection (IFI) in Europe: a review of the literature (PIN3)
• Infection:Clinical and economic burden of hospital onset health care facility acquired clostridium difficile infection (HO-HCFA-CDI) in Europe: a systematic review(PIN10)
• Infection:Cost analysis of voriconazole versus itraconazole for prophylaxis of invasive fungal infection (ifi) in allogeneic hematopoietic stem cell transplant (HSCT) in Canada, France, Germany, and the United States (PIN30)
• Infection:Modeling the long term clinical outcomes and health care cost impact of initiating treatment with atazanavir/r compared with darunavir/r, lopinavir/r and efavirenz for HIV-1 infected treatment-naïve patients: country results for Italy, Spain, Portugal and UK (PIN73)
• Infection:Cost-effectiveness of atazanavir/r compared to darunavir/r in Germany (PIN82)
  Mental health:The cost-effectiveness of paliperidone ER in Spain (PMH33)
• Neurological disorders:Cost minimization analysis of fingolimod compared to natalizumab in patients with relapse remitting multiple sclerosis in the Netherlands (PND33)
• Urinary/kidney disorders: Sources of heterogeneity among overactive bladder clinical trial estimates of tolterodine and fesoterodine reductions of urgency urinary incontinence episodes relative to placebo (PUK3)
• Urinary/kidney disorders: Mixed treatment comparisons of immunosuppressants following renal transplant (PUK5)

 

Session II:Monday, 7 November 8:00-19:30

• Health care use & policy studies: Identifying factors influencing drug reimbursement in Scotland (PHP104)
• Cardiovascular disorders: Ticagrelor for the treatment of acute coronary syndromes (ACS): a Dutch analysis based on the PLATO trial (PCV87)

 

Session III: Tuesday, 8 November 8:00-16:00

• Research on methods:Identification of diseases for EQ-5D bolt-on item development: an empirical approach (PRM39)
• Cancer: Cost-of-illness study of human papillomavirus cancers in England (PCN44)
• Cancer: Cost effectiveness of zoledronic acid versus pamidronate or no therapy for the treatment of bone metastases secondary to prostate cancer (PCN73)
• Diabetes/endocrine disorders: Reduction in comorbidities and cost savings associated with biochemical control in patients with Cushing's disease: a literature-based analysis (PDB50)
• Respiratory-related disorders:Budget impact analysis of immunotherapy in patients with grass pollen allergic rhinitis (PRS9)
• Respiratory-related disorders:Budget impact analysis of immunotherapy in patients with birch allergic rhinitis (PRS11)
• Respiratory-related disorders:Cost-effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinitis (PRS41)

 

Workshops

 

Session II: Sunday, 6 November 2011: 17:15-18:15

• Patient-reported outcomes & preference-based research:Valuing health in economic evaluations; innovative responses to methodological challenges (W14)
  
• ISPOR Invite Washington